Biomarker Guided Discharge of Heart Failure Patients
Key facts
- Where
- Ottawa, CanadaSee the site
Where in Canada
- University of Ottawa Heart InstituteOttawa, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Heart Institute Research Corporation
- Trial code
- NCT03103932
- Record updated
- 6 May 2026
- Original description
This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.Read full original descriptionShow less
BiomarkeR cAndidates to Guide Discharge of Patients Admitted to Hospital With heARt Failure
This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.
Inclusion: Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria.
Exclusion: Patient who has participated in another research trial involving an investigational product in the past 30 days; Patient listed for heart transplant, or admitted specifically for transplant workup; Patient with life expectancy of less than 6 months, or has major co-morbidities such as new stroke, cancer, pneumonia, or other serious life threatening illness; Patient with conditions that will make it difficult to discharge from hospital such as a fall or waiting for a long term care bed; Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the trial, or may bias the result of the trial, or the patient's ability to participate in the trial; Patient with end stage organ failure; Kidney: creatinine >350 μmol/L or Estimated GFR ≤15 ml/min; Liver dysfunction: liver function test >2.5 times normal; Lungs: pulmonary FEV1<50% predicted; Patient unable to provide blood samples or cannot participate in follow-up; Patient requiring intubation; Patient with an admission NTproBNP measurement of >30,000 pg/ml; Patient in cardiogenic shock.